Skip to main content
OpenTrials
Completed

NCT Number: NCT02129127

Drug-Coated Chocolate PTA Balloon in Patients With Peripheral Arterial Disease - The ENDURE Trial

This first-in-man study is to evaluate the Drug-Coated Chocolate (DCC) Balloon for percutaneous arterial angioplasty in patients with symptomatic peripheral arterial disease. The study focuses on acute device performance and peri-procedural safety and also seeks to further characterize the performance of the device.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Peripheral Vascular Disease Cardiovascular Diseases Peripheral Vascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Universitats Herzzentrum Bad Krozingen, Bad Krozingen, Germany

Loading trial locations.

About this study

This is a prospective, multi-center, single-arm study. Symptomatic lower extremity Peripheral Arterial Disease (PAD) patients presenting for endovascular revascularization will be enrolled in the study if they meet all entry criteria. The study will include patients from New Zealand and the European Union. The endpoints were designed to establish safety of the DCC and to identify long-term clinical benefits of this technology.

The patients treated in this study will be designated into the above the knee (ATK) follow-up schedule if they are treated with the DCC in the SFA or Popliteal vessels. This schedule calls for clinical visits with duplex ultrasounds at 1,6 and 12 months. Patients will be designated into the below the knee (BTK) follow-up schedule if they are treated with the DCC in the Peroneal, Anterior Tibial, Posterior Tibial or Pedal vessels. These patients will have clinical visits at 1, 3 and 6 months with duplex ultrasound at the 1 and 6 months visits only.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Intermittent claudication or critical limb ischemia
  • Atherosclerotic target lesion >70% stenosis
  • Reference vessel diameter (RVD) between 2.0 and 6.0mm
  • Angiographic evidence of distal run-off
  • Target lesion length <150mm that consists of no more than two adjacent lesions( < 25mm apart) and is able to be completely covered with inflation of no more than two DCC devices

Key Exclusion Criteria:

  • Acute limb ischemia or thrombolytic therapy
  • Known and relevant allergies/hypersensitivities
  • Known impaired renal function
  • Known bleeding disorder
  • Severe calcification at the target lesion
  • Previous bypass or stent at, or proximal to, target vessel
  • Aneurysm in target limb
  • Prior major limb amputation
  • Use of a any of the following: re-entry device, atherectomy, laser or other ablation procedure, or cutting/scoring balloon at the target lesion; use of drug eluting stent, or non-study drug coated balloon in the target limb.

Treatment and study plan

Paclitaxel Coated Chocolate Balloon Angioplasty

Device

Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel

Primary outcomes

  1. Late Lumen Loss (LLL)

    Time frame: 3 Months (BTK) or 6 Months (ATK)

    LLL is determined by assessing the difference between the minimum lumen diameter (MLD) immediately after treatment with the DCC and the MLD at angiographic follow-up. LLL will determined by the Angiographic Core Laboratory.

Secondary outcomes

  1. Device Success

    Time frame: approx 1 hour

    This is defined as the percentage of procedures that accomplish less than 30% residual stenosis without flow-limiting dissection at target lesion after DCC treatment.

  2. Technical Success

    Time frame: approx 1 hour

    This is defined as the percentage of cases in which the DCC is able to be delivered to and inflated at the intended target lesion location successfully.

  3. Device Related Adverse Events (AEs)

    Time frame: 30 days

    Occurrence and Severity of any DCC Related AEs will be analyzed

  4. Freedom from Target Lesion Revascularization (TLR)

    Time frame: 30 days / 3 Months (BTK only) / 6 Months / 12 Months (ATK only)

    This will calculate the number of patients who do not require a clinically indicated TLR. Clinically indicated TLR is defined as any repeat percutaneous intervention at the DCC target lesion or bypass surgery at the DCC target vessel performed for >50% restenosis or another complication of the target lesion

  5. Amputation Free Survival

    Time frame: 30 days / 3 Months (BTK only) / 6 Months / 12 Months (ATK only)

    This is a composite endpoint which counts the number of patients who experience limb salvage. Patients will fail this endpoint if they undergo a major amputation (defined as unplanned amputation at or above the ankle) or if a procedure related death occurs.

  6. Patency

    Time frame: 6 Months / 12 Months (ATK only)

    The percentage of cases in which the treated lesion is patent. Patency is demonstrated by a Peak Systolic Velocity ratio <2.5 at the target lesion assessed on Duplex Ultrasound without the need for re-intervention.

Sponsors and collaborators

Lead sponsor

TriReme Medical, LLC

Industry

Registry information

Official study title

First in Human Evaluation of the Drug-Coated Chocolate Balloon for Percutaneous Transluminal Revascularization of Infrainguinal Arterial Disease

Acronym: ENDURE

Important dates

Study start
2014
Primary completion
2015
Study completion
2017
First posted
May 2, 2014
Registry last updated
Apr 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.